Quinine Treatment Selects the pfnhe-1 ms4760-1 Polymorphism in Malian Patients with Falciparum Malaria

Bibliographic Details
Main Author: Kone, Aminatou
Publication Date: 2013
Other Authors: Mu, Jianbing, Maiga, Hamma, Beavogui, Abdoul H., Yattara, Omar, Sagara, Issaka, Tekete, Mamadou M., Traore, Oumar B., Dara, Antoine, Dama, Souleymane, Diallo, Nouhoum, Kodio, Aly, Traore, Aliou, Bjoerkman, Anders, Gil, José Pedro, Doumbo, Ogobara K., Wellems, Thomas E., Djimde, Abdoulaye A.
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10400.1/11304
Summary: Background. The mechanism of Plasmodium falciparum resistance to quinine is not known. In vitro quantitative trait loci mapping suggests involvement of a predicted P. falciparum sodium-hydrogen exchanger (pfnhe-1) on chromosome 13. Methods. We conducted prospective quinine efficacy studies in 2 villages, Kolle and Faladie, Mali. Cases of clinical malaria requiring intravenous therapy were treated with standard doses of quinine and followed for 28 days. Treatment outcomes were classified using modified World Health Organization protocols. Molecular markers of parasite polymorphisms were used to distinguish recrudescent parasites from new infections. The prevalence of pfnhe-1 ms4760-1 among parasites before versus after quinine treatment was determined by direct sequencing. Results. Overall, 163 patients were enrolled and successfully followed. Without molecular correction, the mean adequate clinical and parasitological response (ACPR) was 50.3% (n = 163). After polymerase chain reaction correction to account for new infections, the corrected ACPR was 100%. The prevalence of ms4760-1 increased significantly, from 26.2% (n = 107) before quinine treatment to 46.3% (n = 54) after therapy (P = .01). In a control sulfadoxine-pyrimethamine study, the prevalence of ms4760-1 was similar before and after treatment. Conclusions. This study supports a role for pfnhe-1 in decreased susceptibility of P. falciparum to quinine in the field.
id RCAP_4ad2c633b4e1816648e2d12b4f3d779c
oai_identifier_str oai:sapientia.ualg.pt:10400.1/11304
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Quinine Treatment Selects the pfnhe-1 ms4760-1 Polymorphism in Malian Patients with Falciparum MalariaIn-Vitro susceptibilityDrug-resistant malariaPlasmodium-FalciparumNa+/H+ exchangerMicrosatellite variationsChloroquine resistanceAntimalarial-drugsAssociationResponsesEfficacyBackground. The mechanism of Plasmodium falciparum resistance to quinine is not known. In vitro quantitative trait loci mapping suggests involvement of a predicted P. falciparum sodium-hydrogen exchanger (pfnhe-1) on chromosome 13. Methods. We conducted prospective quinine efficacy studies in 2 villages, Kolle and Faladie, Mali. Cases of clinical malaria requiring intravenous therapy were treated with standard doses of quinine and followed for 28 days. Treatment outcomes were classified using modified World Health Organization protocols. Molecular markers of parasite polymorphisms were used to distinguish recrudescent parasites from new infections. The prevalence of pfnhe-1 ms4760-1 among parasites before versus after quinine treatment was determined by direct sequencing. Results. Overall, 163 patients were enrolled and successfully followed. Without molecular correction, the mean adequate clinical and parasitological response (ACPR) was 50.3% (n = 163). After polymerase chain reaction correction to account for new infections, the corrected ACPR was 100%. The prevalence of ms4760-1 increased significantly, from 26.2% (n = 107) before quinine treatment to 46.3% (n = 54) after therapy (P = .01). In a control sulfadoxine-pyrimethamine study, the prevalence of ms4760-1 was similar before and after treatment. Conclusions. This study supports a role for pfnhe-1 in decreased susceptibility of P. falciparum to quinine in the field.Oxford Univ Press IncSapientiaKone, AminatouMu, JianbingMaiga, HammaBeavogui, Abdoul H.Yattara, OmarSagara, IssakaTekete, Mamadou M.Traore, Oumar B.Dara, AntoineDama, SouleymaneDiallo, NouhoumKodio, AlyTraore, AliouBjoerkman, AndersGil, José PedroDoumbo, Ogobara K.Wellems, Thomas E.Djimde, Abdoulaye A.2018-12-07T14:53:00Z2013-022013-02-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/11304eng0022-18991537-661310.1093/infdis/jis691info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-02-18T17:36:43Zoai:sapientia.ualg.pt:10400.1/11304Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T20:28:33.578375Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Quinine Treatment Selects the pfnhe-1 ms4760-1 Polymorphism in Malian Patients with Falciparum Malaria
title Quinine Treatment Selects the pfnhe-1 ms4760-1 Polymorphism in Malian Patients with Falciparum Malaria
spellingShingle Quinine Treatment Selects the pfnhe-1 ms4760-1 Polymorphism in Malian Patients with Falciparum Malaria
Kone, Aminatou
In-Vitro susceptibility
Drug-resistant malaria
Plasmodium-Falciparum
Na+/H+ exchanger
Microsatellite variations
Chloroquine resistance
Antimalarial-drugs
Association
Responses
Efficacy
title_short Quinine Treatment Selects the pfnhe-1 ms4760-1 Polymorphism in Malian Patients with Falciparum Malaria
title_full Quinine Treatment Selects the pfnhe-1 ms4760-1 Polymorphism in Malian Patients with Falciparum Malaria
title_fullStr Quinine Treatment Selects the pfnhe-1 ms4760-1 Polymorphism in Malian Patients with Falciparum Malaria
title_full_unstemmed Quinine Treatment Selects the pfnhe-1 ms4760-1 Polymorphism in Malian Patients with Falciparum Malaria
title_sort Quinine Treatment Selects the pfnhe-1 ms4760-1 Polymorphism in Malian Patients with Falciparum Malaria
author Kone, Aminatou
author_facet Kone, Aminatou
Mu, Jianbing
Maiga, Hamma
Beavogui, Abdoul H.
Yattara, Omar
Sagara, Issaka
Tekete, Mamadou M.
Traore, Oumar B.
Dara, Antoine
Dama, Souleymane
Diallo, Nouhoum
Kodio, Aly
Traore, Aliou
Bjoerkman, Anders
Gil, José Pedro
Doumbo, Ogobara K.
Wellems, Thomas E.
Djimde, Abdoulaye A.
author_role author
author2 Mu, Jianbing
Maiga, Hamma
Beavogui, Abdoul H.
Yattara, Omar
Sagara, Issaka
Tekete, Mamadou M.
Traore, Oumar B.
Dara, Antoine
Dama, Souleymane
Diallo, Nouhoum
Kodio, Aly
Traore, Aliou
Bjoerkman, Anders
Gil, José Pedro
Doumbo, Ogobara K.
Wellems, Thomas E.
Djimde, Abdoulaye A.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Sapientia
dc.contributor.author.fl_str_mv Kone, Aminatou
Mu, Jianbing
Maiga, Hamma
Beavogui, Abdoul H.
Yattara, Omar
Sagara, Issaka
Tekete, Mamadou M.
Traore, Oumar B.
Dara, Antoine
Dama, Souleymane
Diallo, Nouhoum
Kodio, Aly
Traore, Aliou
Bjoerkman, Anders
Gil, José Pedro
Doumbo, Ogobara K.
Wellems, Thomas E.
Djimde, Abdoulaye A.
dc.subject.por.fl_str_mv In-Vitro susceptibility
Drug-resistant malaria
Plasmodium-Falciparum
Na+/H+ exchanger
Microsatellite variations
Chloroquine resistance
Antimalarial-drugs
Association
Responses
Efficacy
topic In-Vitro susceptibility
Drug-resistant malaria
Plasmodium-Falciparum
Na+/H+ exchanger
Microsatellite variations
Chloroquine resistance
Antimalarial-drugs
Association
Responses
Efficacy
description Background. The mechanism of Plasmodium falciparum resistance to quinine is not known. In vitro quantitative trait loci mapping suggests involvement of a predicted P. falciparum sodium-hydrogen exchanger (pfnhe-1) on chromosome 13. Methods. We conducted prospective quinine efficacy studies in 2 villages, Kolle and Faladie, Mali. Cases of clinical malaria requiring intravenous therapy were treated with standard doses of quinine and followed for 28 days. Treatment outcomes were classified using modified World Health Organization protocols. Molecular markers of parasite polymorphisms were used to distinguish recrudescent parasites from new infections. The prevalence of pfnhe-1 ms4760-1 among parasites before versus after quinine treatment was determined by direct sequencing. Results. Overall, 163 patients were enrolled and successfully followed. Without molecular correction, the mean adequate clinical and parasitological response (ACPR) was 50.3% (n = 163). After polymerase chain reaction correction to account for new infections, the corrected ACPR was 100%. The prevalence of ms4760-1 increased significantly, from 26.2% (n = 107) before quinine treatment to 46.3% (n = 54) after therapy (P = .01). In a control sulfadoxine-pyrimethamine study, the prevalence of ms4760-1 was similar before and after treatment. Conclusions. This study supports a role for pfnhe-1 in decreased susceptibility of P. falciparum to quinine in the field.
publishDate 2013
dc.date.none.fl_str_mv 2013-02
2013-02-01T00:00:00Z
2018-12-07T14:53:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.1/11304
url http://hdl.handle.net/10400.1/11304
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 0022-1899
1537-6613
10.1093/infdis/jis691
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Oxford Univ Press Inc
publisher.none.fl_str_mv Oxford Univ Press Inc
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833598676780449792